Ranked among the top 20 nationally and a leader in otolaryngology research and medical education.
Patients with recurrent respiratory papillomatosis (RRP) may soon have hope thanks to the positive results from a clinical trial testing an experimental vaccine, INO-3107, administered across eight sites including UC Davis Health. Study participants had between two and eight surgeries, in the year before receiving the treatment. Overall, 81.3% of patients in the trial had fewer surgeries in the year after receiving INO-3107 compared to the prior year.
In an article published in the journal Facial Plastic Surgery Clinics of North America, Travis Tollefson, M.D., professor in the Department of Otolaryngology, and colleagues, outline several best practices for surgeons approaching otoplasty. For Tollefson, who also directs the Division of Facial Plastic and Reconstructive Surgery, the process begins with in-depth conversations with families.
UC Davis Health researchers have begun a clinical trial, called REVIVE, using stem cells from a biopsy of a patient’s thigh muscle and injecting them into the patient’s tongue. Researchers believe the stem cells will fuse with existing muscle fibers to increase tongue strength and patients’ ability to swallow. The principal investigator of the study is Peter Belafsky, M.D., M.P.H., Ph.D., director of the UC Davis Center for Voice and Swallowing.
We welcome the opportunity to partner with you in caring for your patient.
Our specialists are available when the need arises. Learn more about a specific health specialty.
The goal of clinical studies at UC Davis Health is to discover and share knowledge to advance health.
A U.S. News & World Report best hospital in cancer, cardiology, heart & vascular surgery, diabetes & endocrinology, ENT, geriatrics, neurology & neurosurgery, obstetrics & gynecology, and pulmonology & lung surgery.
We offer comprehensive, leading-edge, and evidenced-based treatments across the entire spectrum of Otolaryngology care. Our expertise encompasses medical and surgical treatments for birth defects, tumors, degenerative diseases, trauma and other problems that impair hearing, balance, taste or smell.
One of ~56 U.S. cancer centers designated “comprehensive” by the National Cancer Institute.
UC Davis Medical Center received Healthgrades® America’s 100 Best Hospitals Award for 2024, placing us among the top 2% of hospitals nationwide for overall clinical performance. We also received accolades for high-quality patient care, known as Specialty Excellent Awards, in five areas including cardiac, neurosciences, gastrointestinal, critical care and pulmonary specialties.
UC Davis Medical Center has been recognized as one of the nation’s top hospitals by the 2023 edition of Becker’s Hospital Review’s “Great hospitals in America” list.
UC Davis Medical Center has received Magnet® recognition, the nation’s highest honor for nursing excellence.
Ranked Sacramento’s #1 hospital by U.S. News, and high-performing in COPD, colon cancer surgery, diabetes, heart attack, heart failure, hip fracture, hip replacement, kidney failure, leukemia, lymphoma & myeloma, lung cancer surgery, ovarian cancer surgery, pneumonia, prostate cancer surgery, stroke, TAVR, uterine cancer surgery, gastroenterology & GI surgery, and orthopedics.